What is a BRAF-V600E mutation?

(1:49)

Treatment approaches for BRAF V600E mutant metastatic colorectal cancer

(1:17)

BREAKWATER: New Standard of Care Frontline Regimen for BRAF V600E-Mutant mCRC

(2:42)

The evolving treatment paradigm for BRAF V600E-mutant mCRC

(2:28)

Genetics and Targeting of Advanced Thyroid Cancer - M. Ringel

(21:14)

BRAFV600E in Papillary Thyroid Cancer

(2:5)

Evolving Insight from Genetics and Genomics

(20:47)

Why is it so important to know if you have BRAF-V600E?

(1:43)

Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib

(2:56)

Encorafenib + cetuximab (EC) BREAKWATER Study in BRAF V600E-Mutant Metastatic Colorectal Cancer

(4:3)

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

(5:19)

BRAF V600E As A Target In Advanced Non Small Cell Lung Cancer

(2:2)

Chronic pancreatitis - causes, symptoms, diagnosis, treatment, pathology

(9:2)

6 Warning Signs of Brain Tumors

(2:28)

Peripheral neuropathy: Mayo Clinic Radio

(8:31)

SWOG S2107: encorafenib, cetuximab ± nivolumab in previously treated, MSS, BRAFV600E CRC

(2:23)

Targeted Therapies for BRAF V600E-Mutated mNSCLC

(3:53)

Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma

(1:32)

Novel treatment strategies for BRAF V600E-mutant NSCLC

(1:26)

Combination therapies with vemurafenib in BRAF v600E–mutant cancers

(2:4)

Dr. Lieu on the Predictive Value of BRAF V600E Mutations in CRC

(1:55)